1036 related articles for article (PubMed ID: 33329598)
1. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
2. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
Cheng SL
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
[TBL] [Abstract][Full Text] [Related]
3. Biologics in severe asthma.
Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
[TBL] [Abstract][Full Text] [Related]
4. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
6. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
7. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
8. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
10. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
11. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
12. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
13. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.
Chen CY; Wu KH; Guo BC; Lin WY; Chang YJ; Wei CW; Lin MJ; Wu HP
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203353
[TBL] [Abstract][Full Text] [Related]
14. [Biologicals in the Treatment of Bronchial Asthma].
Haasler I; Taube C
Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
[TBL] [Abstract][Full Text] [Related]
15. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
16. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
17. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
Parulekar AD; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
[TBL] [Abstract][Full Text] [Related]
18. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibodies for the Management of Severe Asthma.
Rubinsztajn R; Chazan R
Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
[TBL] [Abstract][Full Text] [Related]
20. The potential of biologics for the treatment of asthma.
Pelaia G; Vatrella A; Maselli R
Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
